Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added. The previous notice about a lapse in government funding and related operating status information (Revision: v3.4.1) was removed.
    Difference
    0.4%
    Check dated 2026-02-11T02:07:25.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status was added. The revision tag changed from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-03T22:36:02.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option and updated footer labels to 'Last Update Submitted that Met QC Criteria' with a 'Revision: v3.4.0' note.
    Difference
    0.2%
    Check dated 2026-01-27T16:59:17.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4; no trial details or visible content were modified.
    Difference
    0.1%
    Check dated 2026-01-20T15:40:53.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    A new Locations section is added with District of Columbia listed as a study location, replacing the prior District of Columbia Locations entry and removing the HHS Vulnerability Disclosure link.
    Difference
    0.2%
    Check dated 2025-12-22T22:13:36.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision metadata updated: added v3.3.2 and removed v3.3.1. The change is limited to the page’s version information and does not modify the study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T12:52:35.000Z thumbnail image

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.